Ukrainian Journal of Perinatology and Pediatrics. 2026.1(105): 55-62. doi: 10.15574/PP.2026.1(105).5562
Chernov А. V., Serbeniuk А. V.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Chernov АV, Serbeniuk АV. (2026). Vascular growth factors as diagnostic markers of preeclampsia severity and duration of pregnancy prolongation in women giving birth for the first time. Ukrainian Journal of Perinatology and Pediatrics. 1(105): 55-62. doi: 10.15574/PP.2026.1(105).5562.
Article received: Dec 28, 2025. Accepted for publication: Feb 16, 2026.

Aim – to determine the role of vascular growth factors in the development and progression of preeclampsia (PE) in women giving birth for the first time, to optimize obstetric tactics in this category of pregnant women.
Materials and methods. 101 pregnancy histories from 28 to 40 weeks in women with preeclampsia giving birth for the first time were analyzed. Group I – 40 pregnant women with moderate preeclampsia, group II – 36 pregnant women with severe preeclampsia, control group (CG) – 25 pregnant women the physiological course of this pregnancy. The study of the content of sFlt-1 (soluble FMS-like tyrosine kinase-1), PlGF proteins (placental growth factor) and soluble endoglin (Seng) was carried out by the method of immuno-enzyme analysis.
Results. In group I pregnant women, the level of sFlt-1 was 36124.6±4820.2 pg/ml, which is significantly lower than in group II pregnant women – 54826.4±442.2 pg/ml and significantly higher than in group II pregnant women – 3299.4±144.2 pg/ml, respectively. The level of sEng in groups I and II was significantly higher than in CG 69940±1234.2 pg/ml, 92580±1784.4 pg/ml versus 5440±684.6 pg/ml, respectively. The level of endoglin in group I was 69940±1234.2 pg/ml, significantly lower than that of pregnant women in group II – 92580±1784.4 pg/ml. The level of PlGF in group I was 64.8±4.6 pg/ml and group II was 48.2±4.2 pg/ml, significantly lower than that of CG – 428.8±46.2 pg/ml. In group I, the level of PlGF was 64.8±4.6 pg/ml, significantly higher than that of group II – 48.2±4.2 pg/ml. The angiogenic coefficient (sFlt-1/PlGF) from 28 to 34 weeks in group I is 557.47±42.8, which is significantly lower than group II – 1137.47±62.2 and significantly higher than СG – 7.69±2.2.
Conclusions. For pregnant women with preeclampsia who give birth for the first time, the development of an imbalance of angiogenic growth factors with a predominance of antiangiogenic and a deficiency of proangiogenic agents is characteristic. With high values of the sFlt-1/PlGF ratio, it is not possible to prolong pregnancy for a long time due to the progression of PE and/or deterioration of the fetal condition.
The research was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institution mentioned in the paper.
The authors declare no conflict of interest.
Keywords: pregnant women giving birth for the first time, hypertensive disorders, preeclampsia, vascular endothelial growth factor, placental growth factor, soluble FMS-like tyrosine kinase-1, soluble endoglin, angiogenic ratio.

REFERENCES

1. Amelio GS, Provitera L, Raffaeli G, Tripodi M, Amodeo I, Gulden S et al. (2022, Nov 4). Endothelial dysfunction in preterm infants: The hidden legacy of uteroplacental pathologies. Front Pediatr. 10: 1041919. https://doi.org/10.3389/fped.2022.1041919; PMid:36405831 PMCid:PMC9671930

2. American College of Obstetricians and Gynecologists. (2021). Fetal growth restriction: ACOG Practice Bulletin No. 204. Obstetrics & Gynecology. 137(2): e16-e28. https://doi.org/10.1097/AOG.0000000000004251; PMid:33481528

3. Chaemsaithong P, Sahota DS, Poon LC. (2022., Feb). First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 226; 2 Suppl: S1071-S1097.e2. https://doi.org/10.1016/j.ajog.2020.07.020; PMid:32682859

4. Cindrova-Davies T, Sferruzzi-Perri AN. (2022, Nov). Human placental development and function. Semin Cell Dev Biol. 131: 66-77. https://doi.org/10.1016/j.semcdb.2022.03.039; PMid:35393235 PMCid:PMC10682727

5. Cohen Y, Gutvirtz G, Avnon T, Sheiner E. (2024). Chronic Hypertension in Pregnancy and Placenta-Mediated Complications Regardless of Preeclampsia. Journal of Clinical Medicine. 13(4): 1111. https://doi.org/10.3390/jcm13041111; PMid:38398426 PMCid:PMC10889586

6. Correa‐de‐Araujo R, Yoon S. (2020). Clinical Outcomes in High-Risk Pregnancies Due to Advanced Maternal Age. Journal of Women's Health. 30: 160-167. Epub 2020 Nov 13. https://doi.org/10.1089/jwh.2020.8860; PMid:33185505 PMCid:PMC8020515

7. Gingrich J, Ticiani E, Veiga-Lopez A. (2020, Jul). Placenta Disrupted: Endocrine Disrupting Chemicals and Pregnancy. Trends Endocrinol Metab. 31(7): 508-524. Epub 2020 Apr 2. https://doi.org/10.1016/j.tem.2020.03.003; PMid:32249015 PMCid:PMC7395962

8. Guarga Montori M, Álvarez Martínez A, Luna Álvarez C, Abadía Cuchí N, Mateo Alcalá P, Ruiz-Martínez S. (2021, Jan). Advanced maternal age and adverse pregnancy outcomes: A cohort study. Taiwan J Obstet Gynecol. 60(1): 119-124. https://doi.org/10.1016/j.tjog.2020.11.018; PMid:33494983

9. Gunderson E, Greenberg M, Najem M, Sun B, Alexeeff SE, Alexander J et al. (2025). Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension. JAMA Network Open. 8(1): e2451406. https://doi.org/10.1001/jamanetworkopen.2024.51406; PMid:39874039 PMCid:PMC11775729

10. Gusella A, Martignoni G, Giacometti C. (2024, Jul 18). Behind the Curtain of Abnormal Placentation in Pre-Eclampsia: From Molecular Mechanisms to Histological Hallmarks. Int J Mol Sci. 25(14): 7886. https://doi.org/10.3390/ijms25147886; PMid:39063129 PMCid:PMC11277090

11. Hug L, You D, Blencowe H, Mishra A, Wang Z, Fix MJ et al. (2021, Aug 28). Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment. Lancet. 398(10302): 772-785. https://doi.org/10.1016/S0140-6736(21)01112-0; PMid:34454675 PMCid:PMC8417352

12. Ives CW, Sinkey R, Rajapreyar I, Tita AT, Oparil S. (2020). Preeclampsia – pathophysiology and clinical presentations. Journal of the American College of Cardiology. 76(14): 1690-1702. https://doi.org/10.1016/j.jacc.2020.08.014; PMid:33004135 PMCid:PMC12042644

13. Jansen CHJR, Kastelein AW, Kleinrouweler CE, Van Leeuwen E, De Jong KH et al. (2020, Aug). Development of placental abnormalities in location and anatomy. Acta Obstet Gynecol Scand. 99(8): 983-993. https://doi.org/10.1111/aogs.13834; PMid:32108320 PMCid:PMC7496588

14. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al. (2004). Circulating angiogenic factors and the risk of preeclampsia. The New England Journal of Medicine. 350(7): 672-683. Epub 2004 Feb 5. https://doi.org/10.1056/NEJMoa031884; PMid:14764923 PMCid:PMC12042644

15. Maynard SE, Karumanchi SA. (2011). Angiogenic factors and preeclampsia. Seminars in Nephrology. 31(1): 33-46. https://doi.org/10.1016/j.semnephrol.2010.10.004; PMid:21266263 PMCid:PMC3063446

16. Mintser AP. (2018). Statisticheskie metodyi issledovaniya v klinicheskoy meditsine. Prakticheskaya meditsina. 3: 41-45.

17. Moyer C, Lawrence E, Beyuo T et al. (2023). Stalled progress in reducing maternal mortality globally: what next? The Lancet, 401: 1060-1062. https://doi.org/10.1016/S0140-6736(23)00518-4; PMid:36924780

18. Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, McIntosh JJ. (2021, Nov 6). Vascular Dysfunction in Preeclampsia. Cells. 10(11): 3055. https://doi.org/10.3390/cells10113055; PMid:34831277 PMCid:PMC8616535

19. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H et al. (2019, May). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 145; Suppl 1: 1-33. doi: 10.1002/ijgo.12802. Erratum in: Int J Gynaecol Obstet. 2019 Sep; 146(3): 390-391. https://doi.org/10.1002/ijgo.12892; PMid:31378938

20. Ratnik K, Rull K, Aasmets O, Kikas T, Hanson E, Kisand K et al. (2022, Jul 27). Novel Early Pregnancy Multimarker Screening Test for Preeclampsia Risk Prediction. Front Cardiovasc Med. 9: 932480. https://doi.org/10.3389/fcvm.2022.932480; PMid:35966513 PMCid:PMC9363612

21. Roberts JM, Bell MJ. (2013). If we know so much about preeclampsia, why haven't we cured the disease? Journal of Reproductive Immunology. 99(1-2): 1-9. Epub 2013 Jul 25. https://doi.org/10.1016/j.jri.2013.05.003; PMid:23890710 PMCid:PMC4066309

22. Ryan K, McGrath L, Brookfield K. (2024). Hypertension Management in Pregnancy. Annual Review of Medicine. 75: 251-264. https://doi.org/10.1146/annurev-med-050423-085626; PMid:39586030

23. Shibuya M. (2013). Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. Journal of Biochemistry. 153(1): 13-19. Epub 2012 Nov 21. https://doi.org/10.1093/jb/mvs136; PMid:23172303 PMCid:PMC3528006

24. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. (2006). Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine. 12(6): 642-649. Epub 2006 Jun 4. Erratum in: Nat Med. 2006 Jul; 12(7): 862. https://doi.org/10.1038/nm1429; PMid:16751767 PMCid:PMC12042644

25. Voskamp L, Rousian M, Koerts J et al. (2025). Risk factors for chronic hypertension 5 years after a pregnancy complicated by preeclampsia: a systematic review and meta-analysis. Journal of Hypertension. 43: 939-948. https://doi.org/10.1097/HJH.0000000000003995; PMid:40079836 PMCid:PMC12052050

26. Wardinger JE, Vadakekut ES. (2025, Dec 1). Placental Insufficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-.

27. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH et al. (2005). Circulating levels of the antiangiogenic marker sFlt-1 are increased in first versus second pregnancies. American Journal of Obstetrics and Gynecology. 193(1): 16-22. https://doi.org/10.1016/j.ajog.2005.03.016; PMid:16021053

28. Wu P, Green M, Myers JE. (2023, Jun 30). Hypertensive disorders of pregnancy. BMJ. 381: e071653. https://doi.org/10.1136/bmj-2022-071653; PMid:37391211

29. Zhou Q, Acharya G. (2022, Apr 28). Editorial: Placental Hormones and Pregnancy-Related Endocrine Disorders. Front Endocrinol (Lausanne). 13: 905829. https://doi.org/10.3389/fendo.2022.905829; PMid:35573985 PMCid:PMC9097261